<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694733</url>
  </required_header>
  <id_info>
    <org_study_id>eIRB #937</org_study_id>
    <secondary_id>OCTRI #862</secondary_id>
    <nct_id>NCT00694733</nct_id>
  </id_info>
  <brief_title>Regulation of Cortisol Metabolism and Fat Patterning</brief_title>
  <official_title>Regulation of Cortisol Metabolism and Fat Patterning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if estrogen or testosterone can affect cortisol&#xD;
      levels and where fat builds up in our bodies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be studied 3 or 4 times on the inpatient unit of the Oregon Clinical and&#xD;
      Translational Research Center. During each visit, testing will include measuring the amount&#xD;
      of whole body fat and fat in the stomach area, muscle, and liver; levels of cortisol in the&#xD;
      blood, urine, and fat tissue (taken from a biopsy); how well insulin works (insulin&#xD;
      sensitivity).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure 24-hour CPR, free cortisol, and cortisol binding globulin levels in plasma; HSD 1 activity, glucocorticoid receptor binding, and cortisol levels in adipocytes; and urinary excretion of cortisol, cortisone and their metabolites.</measure>
    <time_frame>Before and after hormone replacement therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure intramyocellular fat and intrahepatic fat by MRS, visceral and subcutaneous abdominal fat by CT scan, body composition (fat mass, lean mass, and bone mass) by DXA, and insulin sensitivity.</measure>
    <time_frame>Before and after hormone replacement therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Obesity</condition>
  <condition>Menopausal Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Men on placebo injections for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women on placebo cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women on estrogen cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>Normal saline injection IM monthly for 4 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo Lupron/Aromatase inhibitor</intervention_name>
    <description>Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Depo-Lupron</other_name>
    <other_name>Testim 1% gel</other_name>
    <other_name>Anastrozole</other_name>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo Lupron/placebo</intervention_name>
    <description>Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Depo-Lupron</other_name>
    <other_name>Testim 1% gel</other_name>
    <other_name>Placebo capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo Cream 1ml applied twice daily for four months</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Placebo cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen cream</intervention_name>
    <description>Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Estradiol cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 postmenopausal women (age 40-62) and 30 men (age 18-45) will be recruited if they&#xD;
             are healthy, at their lifetime maximal weight, have been weight stable for at least&#xD;
             six months prior to entry, have a BMI between 19 and 39.9 kg/m2, and be willing to&#xD;
             commit to not making significant changes to their diet or daily activities while&#xD;
             enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded for potential confounders on body weight, cortisol&#xD;
             production rates, sex steroid metabolism, or contraindications to strong magnetic&#xD;
             fields:&#xD;
&#xD;
               1. Age less than 18 to exclude those who might be experiencing alterations in&#xD;
                  cortisol production or weight as a result of adolescent growth&#xD;
&#xD;
               2. Subjects who exercise &gt; 30 minutes/day, 3 times a week&#xD;
&#xD;
               3. Smokers&#xD;
&#xD;
               4. Heavy alcohol drinkers (&gt; 2 drinks/ day)&#xD;
&#xD;
               5. Subjects with medical diagnosis including diabetes, heart disease, and cancer&#xD;
&#xD;
               6. Subjects with psychiatric illness (i.e., depression, psychosis, bipolar,&#xD;
                  schizophrenia; or are taking medications for these disorders)&#xD;
&#xD;
               7. BMI 40 kg/m2, since obesity influences levels of sex steroids and sex hormone&#xD;
                  binding globulin; or body weight &gt; 136 kg (300 lbs), since this is the weight&#xD;
                  limit for the DEXA and MR machines&#xD;
&#xD;
               8. Presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers&#xD;
                  or aneurysm clips&#xD;
&#xD;
               9. Endocrine diseases affecting body composition, such as untreated hypothyroidism&#xD;
                  or Cushing's syndrome, will be excluded by history and physical examination, or&#xD;
                  by laboratory evaluation if necessary.&#xD;
&#xD;
          -  Women with a contraindication to estrogen use will also be excluded, including: an&#xD;
             estrogen dependent malignancy, active thrombophlebitis, history of deep venous&#xD;
             thrombosis, hypertriglyceridemia, untreated hypertension, cardiovascular disease,&#xD;
             migraine headaches, or current tobacco use.&#xD;
&#xD;
          -  Women with frequent hot flashes or disrupted sleep will also be excluded since they&#xD;
             will be unlikely to tolerate randomization to placebo and continued symptoms and&#xD;
             altered sleep cycles will independently affect cortisol secretion patterns.&#xD;
&#xD;
          -  All volunteers will have had a normal mammogram within the previous 12 months.&#xD;
&#xD;
          -  Any subject with previously unevaluated postmenopausal bleeding will not be included&#xD;
             and, instead, will be referred to a physician for evaluation.&#xD;
&#xD;
          -  Women who underwent surgical menopause (bilateral ovariectomy) must be at least one&#xD;
             year out from their surgery before considered eligible so as to allow weight&#xD;
             stabilization after the procedure.&#xD;
&#xD;
          -  Men will have had a prostate exam by their primary health provider within the previous&#xD;
             year or by the PI at the time of screening for this study.&#xD;
&#xD;
          -  Any subjects taking a blood thinning medication or with an abnormal exam will not be&#xD;
             included and, instead, will be referred to a physician for evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Q. Purnell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU - Center for the Study of Weight Regulation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jonathan Purnell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Menopausal Syndrome</keyword>
  <keyword>Cortisol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

